Physician profile
Gavin Park
NPI 1952744484
$5,399.50
in general payments reported to CMS, 2019-2025
24 companies · $1,298 in 2025
The $1,298 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2021: $955 · 2022: $670 · 2023: $966 · 2024: $1,386 · 2025: $1,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,573 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,572.59 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,415.96 | 2020-2025 | |
| Gilead Sciences, INC. | $648.22 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $333.97 | 2021-2025 | Entyvio, Livtencity |
| Pfizer INC. | $243.52 | 2020-2025 | |
| Janssen Biotech, INC. | $217.96 | 2025 | Tremfya |
| Celgene Corporation | $200.92 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $193.41 | 2024 | Embold Fibered |
| Madrigal Pharmaceuticals | $175.42 | 2025 | Rezdiffra |
| Terumo Medical Corporation | $131.36 | 2024 | Azur Cx Detachable |
| Genzyme Corporation | $116.49 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $112.96 | 2020-2024 | Ocaliva |
| Cook Medical LLC | $102.45 | 2025 | Echotip Insight |
| Regeneron Healthcare Solutions, INC. | $97.31 | 2023-2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $62.50 | 2023 | Terlivaz |
| Alnylam Pharmaceuticals INC. | $55.57 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $55.03 | 2025 | Iqirvo |
| Orphalan INC | $36.23 | 2024 | Cuvrior |
| Lilly USA, LLC | $33.40 | 2024 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $32.97 | 2024 | Zeposia |
| Genentech, INC. | $31.11 | 2023 | Avastin, Tecentriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.78 | 2023-2024 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $25.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.94 | 2023 | Imfinzi |
| Celltrion USA INC. | $22.21 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.